Comparative Pharmacokinetics of Enrofloxacin and Difloxacin as Well as Their Main Metabolites in Dogs

Compendium on Continuing Education for the Practicing Veterinarian

Volumn 21, Issue SUPPL. 12, 1999, Pages 12-18

  Heinen, Ernst ^a  

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0346525980     PISSN: 01931903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Wolfson JS, Hooper DC: Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 2:378-424, 1989.
2. Drlica K, Zhao X: DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 61:377-392, 1997.
3. Watts JL, Salmon SA, Sanchez MS, Yancey RJ: In vitro activity of premafloxacin, a new extended-spectrum fluoroquinolone, against pathogens of veterinary importance. Antimicrob Agents Chemother 41:1190-1192, 1997.
4. Hannan PCT, Windsor GD, de Jong A, Schmeer N, Stegemann M: Comparative susceptibilities of various animal-pathogenic mycoplasmas to fluoroquinolones. Antimicrob Agents Chemother 41: 2037-2040, 1997.
5. Vancutsem PM, Babish JG, Schwark WS: The fluoroquinolone antimicrobials: Structure, antimicrobial activity, pharmacokinetics, clinical use in domestic animals and toxicity. Cornell Vet 80:173-186, 1990.
6. Brown SA: Fluoroquinolones in animal health. J Vet Pharmacol Ther 19:1-14, 1996.
7. Boothe DM: Enrofloxacin revisited. Vet Med 89:744-753, 1994.
8. Tyczkowska K, Hedeen KM, Aucoin DP, Aronson AL: High performance liquid chromatographic method for the simultaneous determination of enrofloxacin and its primary metabolite ciprofloxacin in canine serum and prostatic tissue. J Chromatogr 493:337-346, 1989.
9. Schacht P: Clinical use of quinolones, in Kuhlmann J, Dalhoff A, Zeiler H-J (eds): Quinolone Antibacterials. Berlin, Springer, 1998, pp 421-453.
10. Walker RD, Stein GE, Hauptmann JG, et al: Serum and tissues cage fluid concentrations of ciprofloxacin after oral administration of the drug to healthy dogs. Am J Vet Res 51:896-900, 1990.
11. Schneider M, Thomas E, Boisrame B, Deleforge J: Pharmacokinetics of marbofloxacin in dogs after oral and parenteral administration. J Vet Pharmacol Ther 19:56-61, 1996.
12. Matsumoto S, Takahashi M, Yoshida M, et al: Absorption, distribution and excretion of orbifloxacin in dogs and cats. J Jpn Vet Med Assoc 50:470-474, 1997.
13. Van den Hoven R: A multi-centre observational study on the efficacy of Dicural Palatabs (difloxacin) for the treatment of canine cystitis. J Vet Pharmacol Ther 20(Suppl 1):181-218, 1997.
14. Heinen E, de Jong A, Scheer M: Antimicrobial activity of fluoroquinolones in serum and tissues in turkeys. J Vet Pharmacol Ther 20(Suppl 1):196-197, 1997.
15. Grannemann GR, Snyder, KM, Shu VS: Difloxacin metabolism and pharmacokinetics in humans after single oral doses. Antimicrob Agents Chemother 30: 689-693, 1986.
16. Klassen M, Edberg SC: Measurement of antibiotics in human body fluids: Techniques and significance, in Lorian V (ed): Antibiotics in Laboratory Medicine, ed 4. Baltimore, Williams & Wilkins, 1996, pp 234-243.
17. Drusano GL, Johnson DE, Rosen M, Standiford HC: Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 37:483-490, 1993.
18. Forrest A, Nix DE, Ballow CH, et al: Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37: 1073-1081, 1993.
19. Madaras-Kelly KJ, Ostergaard BE, Baeker Hovde L, Rotschafer JC: Twenty-four-hour area under the concentration-time curve/MIC ratio as a predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother 40:627-632, 1996.
20. Stahlmann R, Lode H: Concentration-effect relationship of the fluoroquinolones, in Kuhlmann J, Dalhoff A, Zeiler H-J (eds): Quinolone Antibacterials. Berlin, Springer, 1998, pp 407-420.
21. Firsov AA, Vostrov SN, Shevchenko AA, et al: MIC-based interspecies prediction of the antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic model. Antimicrob Agents Chemother 42:2848-2852, 1998.
22. Walker RD, Stein GE, Hauptman JG, MacDonald KH: Pharmacokinetic evaluation of enrofloxacin administered orally to healthy dogs. Am J Vet Res 53:2315-2319, 1992.
23. Pirro F, Edingloh M, Schmeer N: Bactericidal and inhibitory activity of enrofloxacin and other fluoroquinolones in small animal pathogens. Proceedings of the Third International Veterinary Symposium on Fluoroquinolones. Suppl Compend Contin Educ Pract Vet 21(12):19-25.
24. Foster AP, DeBoer DJ: The role of Pseudomonas in canine ear disease. Compend Contin Educ Pract Vet 20: 909-919, 1998.
25. Fernades PB, Chu DTW, Bower RR, et al: In vivo evaluation of A-56619 (difloxacin) and A-56620: New aryl-fluoroquinolones. Antimicrob Agents Chemother 29: 201-208, 1986.
26. Kueng K, Riond J-L, Wanner M: Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in four dogs. J Vet Pharmacol Ther 16:462-468, 1993.
27. Cester CC, Schneider M, Toutain PL: Comparative kinetics of two orally administered fluoroquinolones in dogs: Enrofloxacin versus marbofloxacin. Rev Med Vet 147:703-716, 1996.
28. Pirro F, Scheer M, de Jong A: Additive in vitro activity of enrofloxacin and its main metabolite ciprofloxacin. Pisa, Italy, Proc 14th Annual Congress of the ESVD-ECVD, 1997, p 199.
29. Zeiler HJ, Petersen U, Gau W, Ploschke HJ: Antibacterial activity of the metabolites of ciprofloxacin and its significance in the bioassay. Drug Res 37:131-134, 1987.